TG Therapeutics Reports 91% Revenue Surge Driven by BRIUMVI Multiple Sclerosis Treatment
核心洞察
TG Therapeutics reported a remarkable 91% year-over-year revenue increase in Q2 2025, primarily driven by strong sales of its multiple sclerosis (搜索) treatment BRIUMVI.
The company raised its 2025 BRIUMVI U.S. net revenue target to $570-575 million and increased global revenue projections to approximately $585 million.
BRIUMVI has gained regulatory approval in the EU, UK, Switzerland, and Australia, with management citing strong physician confidence and uptake.
TG Therapeutics delivered exceptional financial performance in the second quarter of 2025, with revenue soaring 91% year-over-year, driven primarily by robust sales of its multiple sclerosis (搜索) treatment BRIUMVI. The strong results prompted the company to raise its revenue guidance for the remainder of 2025.
Strong Financial Performance and Raised Guidance
The biotechnology company reported Q2 product revenue of $138.84 million, reflecting the significant commercial success of BRIUMVI. Based on this momentum, TG Therapeutics increased its full-year 2025 BRIUMVI U.S. net revenue target to $570-575 million and raised its global revenue projection to approximately $585 million.
License, milestone, royalty and other revenue also contributed to the growth, rising to $2.3 million from approximately $0.9 million in the prior year period. The company reported Q2 net income of $28.19 million and operating income of $34.84 million.
BRIUMVI's Growing Market Presence
CEO Michael S. Weiss emphasized the strong performance across all business aspects, stating he was "pleased to share that we delivered another strong quarter with solid performance across all aspects of our business, highlighted by the continued momentum of our flagship product BRIUMVI."
The company attributes the revenue growth to strong uptake and increasing physician confidence in BRIUMVI. Management believes the treatment is well positioned to redefine multiple sclerosis (搜索) treatment expectations, reflecting growing acceptance in the medical community.
International Expansion
BRIUMVI has achieved regulatory approval beyond the United States, gaining authorization in the European Union, United Kingdom, Switzerland, and Australia. This international expansion provides additional growth opportunities for the company's flagship multiple sclerosis (搜索) treatment.
Market Reception and Analyst Outlook
Wall Street analysts maintain a positive outlook on TG Therapeutics, with the current average analyst rating classified as "buy." The breakdown includes 7 "strong buy" or "buy" recommendations, 1 "hold," and 1 "sell" or "strong sell" rating.
The median 12-month price target stands at $46.00, representing approximately 23.9% upside from the August 1 closing price of $35.02. The stock's valuation metrics show it recently traded at 27 times the next 12-month earnings, compared to a price-to-earnings ratio of 36 three months prior.